Pitavastatin

Pitavastatin (NK-104) is a potent hydroxymethylglutaryl-CoA (HMG-CoA) reductase inhibitor. Pitavastatin inhibits cholesterol synthesis from acetic acid with an IC50 of 5.8 nM in HepG2 cells. Pitavastatin is an efficient hepatocyte low-density lipoprotein-cholesterol (LDL-C) receptor inducer. Pitavastatin also possesses anti-atherosclerotic, anti-asthmatic, anti-osteoarthritis, antineoplastic, neuroprotective, hepatoprotective and reno-protective effects[1][2][3][8].

Product Specifications

CAS Number

[147511-69-1]

Product Name Alternative

NK-104

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

Apoptosis; Autophagy; HMG-CoA Reductase (HMGCR) ; Mitophagy

Type

Reference compound

Related Pathways

Apoptosis; Autophagy; Metabolic Enzyme/Protease

Applications

Cancer-programmed cell death

Field of Research

Cancer; Metabolic Disease; Neurological Disease; Cardiovascular Disease

Assay Protocol

https://www.medchemexpress.com/pitavastatin.html

Purity

99.83

Solubility

DMSO : 100 mg/mL (ultrasonic)

Smiles

O=C(O)C[C@H](O)C[C@H](O)/C=C/C1=C(C2=CC=C(F)C=C2)C3=CC=CC=C3N=C1C4CC4

Molecular Formula

C25H24FNO4

Molecular Weight

421.46

Precautions

H302, H315, H319, H335

References & Citations

[1]Morikawa S, et al. Relative induction of mRNA for HMG CoA reductase and LDL receptor by five different HMG-CoA reductase inhibitors in cultured human cells. J Atheroscler Thromb. 2000;7 (3) :138-44.|[2]Katsuki S, et al. Nanoparticle-mediated delivery of pitavastatin inhibits atherosclerotic plaque destabilization/rupture in mice by regulating the recruitment of inflammatory monocytes. Circulation. 2014 Feb 25;129 (8) :896-906.|[3]Tajiri K, et al. Pitavastatin regulates helper T-cell differentiation and ameliorates autoimmune myocarditis in mice. Cardiovasc Drugs Ther. 2013 Oct;27 (5) :413-24.|[4]Hamano T, et al. Pitavastatin decreases tau levels via the inactivation of Rho/ROCK. Neurobiol Aging. 2012 Oct;33 (10) :2306-20.|[5]de Wolf E, et al.Dietary geranylgeraniol can limit the activity of pitavastatin as a potential treatment for drug-resistant ovarian cancer.Sci Rep. 2017 Jul 14;7 (1) :5410.|[6]Demir B, et al. The Effects of Pitavastatin on Nuclear Factor-Kappa B and ICAM-1 in Human Saphenous Vein Graft Endothelial Culture. Cardiovasc Ther. 2019 May 2;2019:2549432.|[7]Hayashi T, et al. A new HMG-CoA reductase inhibitor, pitavastatin remarkably retards the progression of high cholesterol induced atherosclerosis in rabbits. Atherosclerosis. 2004 Oct;176 (2) :255-63.|[8]Sahebkar A, et al. A comprehensive review on the lipid and pleiotropic effects of pitavastatin. Prog Lipid Res. 2021 Nov;84:101127.

Shipping Conditions

Room Temperature

Storage Conditions

-20°C, 3 years; 4°C, 2 years (Powder)

Scientific Category

Reference compound1

Clinical Information

Launched

Citation 01

Acta Biochim Biophys Sin (Shanghai) . 2024 Apr 25;56 (4) :621-633.|Acta Pharm Sin B. 2020 May;10 (5) :850-860.|Biochem Pharmacol. 2019 Nov:169:113612.|bioRxiv. 2024 June 11.|Braz J Med Biol Res. 2025 Aug 22:58:e14540.|J Hepatol. 2021 Aug;75 (2) :363-376.|Proteomics. 2023 Aug;23 (16) :e2300041.|Acta Biochim Biophys Sin (Shanghai) . 2024 Apr 25;56 (4) :621-633.|Antioxidants (Basel) . 2024 May 29;13 (6) :667.|Bioorg Chem. 2024 Jun:147:107369.|Research Square Preprint. 2024 Apr 9.|Sci Data. 2024 Sep 19;11 (1) :1024.